# Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

> **NCT06333769** · PHASE2 · COMPLETED · sponsor: **Fujian Cancer Hospital** · enrollment: 38 (actual)

## Conditions studied

- Mid-low Rectal Cancer

## Interventions

- **RADIATION:** Short-course Radiotherapy
- **DRUG:** Tislelizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT06333769
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-12
- **Primary completion:** 2025-08-10
- **Final completion:** 2025-08-14
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333769, "Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06333769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*